As currently available tau PET ligands bind AD-like mixed 3R/4R tau pathology, the utility of tau PET in pure 3R or 4R tauopathies, such as progressive supranuclear palsy and corticobasal degeneration, has shown to be less persuasive [57]. Here, MAPT is linked to Alzheimer disease.